Stoke Therapeutics’ (STOK) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note published on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $22.00 target price on the stock. STOK has been the subject of a number of other reports. Leerink Partnrs raised Stoke […]
More Stories
Invesco Mortgage Capital (NYSE:IVR) Posts Quarterly Earnings Results
Invesco Mortgage Capital (NYSE:IVR – Get Free Report) announced its quarterly earnings results on Tuesday. The real estate investment trust...
Regal Rexnord (NYSE:RRX) Updates FY24 Earnings Guidance
Regal Rexnord (NYSE:RRX – Get Free Report) updated its FY24 earnings guidance on Monday. The company provided earnings per share...
QUALCOMM (NASDAQ:QCOM) Given Buy Rating at Benchmark
QUALCOMM (NASDAQ:QCOM – Get Free Report)‘s stock had its “buy” rating restated by research analysts at Benchmark in a report...
Entegris (NASDAQ:ENTG) Releases Earnings Results, Misses Expectations By $0.01 EPS
Entegris (NASDAQ:ENTG – Get Free Report) issued its quarterly earnings results on Monday. The semiconductor company reported $0.77 earnings per...
Woodmont Investment Counsel LLC Sells 5,962 Shares of Emerson Electric Co. (NYSE:EMR)
Woodmont Investment Counsel LLC reduced its stake in Emerson Electric Co. (NYSE:EMR – Free Report) by 9.4% during the 3rd...
Washington Trust Bank Reduces Position in The PNC Financial Services Group, Inc. (NYSE:PNC)
Washington Trust Bank cut its stake in shares of The PNC Financial Services Group, Inc. (NYSE:PNC – Free Report) by...